Thanks largely to news of a crucial legal settlement, GSK ( GSK 5.84%) was one of the better-performing big pharma stocks on Wednesday. Relieved investors showed their appreciation by collectively ...
In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...
The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...
Zantac settlement should ease investors’ nervousness but long-standing concerns about drugmaker’s pipeline remain ...
KEY TAKEAWAYS GSK shares in London jumped 5% Thursday after the British pharmaceutical giant said it has resolved most of the ...
GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...
1d
GSK’s $2.2 billion Zantac settlement today put its shares top of the FTSE 100, albeit still well short of their level before ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback